Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
The grants include 17,850 share options and 10,500 restricted share units for new non-officer employees, the company said.
- On October 1, 2026, Xenon Pharmaceuticals Inc. announced equity inducement grants to eight new non-officer employees consisting of 17,850 share options and 10,500 restricted share units.
- Based in Vancouver, British Columbia, and Boston, Massachusetts, Xenon is a neuroscience-focused biopharmaceutical company dedicated to drug discovery and commercialization of life-changing therapeutics.
- The Compensation Committee approved the awards under the Amended and Restated 2025 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635.
- Restricted share unit awards will vest as to 25% of the underlying shares on each of the first four anniversaries of the grant date, subject to continued service.
- Xenon continues advancing an early-stage portfolio of potassium and sodium channel modulators, including KV7 and NaV1.7 programs currently in Phase 1 development for potential pain treatment.
12 Articles
12 Articles
St Catharines Standard
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, BC and BOSTON, MA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants…
Hastings Tribune
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today…
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 62,500 restricted stock units
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) – Novumpr
LONDON & NEW YORK–(BUSINESS WIRE)– Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to one senior leader and ten newly hired non-executive employees. The equity awards for the […]
Coverage Details
Bias Distribution
- 50% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
